T-Cell Boosting Mixing Device for Sterile Neurotransmitter Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current T-cell immunotherapy protocols face challenges in enhancing the invasion and functionality of T-cells into tumor-bearing organs, particularly due to low CD3 zeta expression in T-cells of cancer patients, which limits their ability to effectively combat cancer and infectious diseases.
Innovation Solution
A method involving the exposure of T-cells to neurotransmitters like dopamine and GnRH-II, along with specific ion channel blockers, to upregulate CD3 zeta expression and enhance T-cell activity, combined with a mixing device for sterile and controlled substance exposure, boosting T-cell invasion and disease-fighting capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If T-cell immunotherapy protocols are used to treat cancer, then T-cells can be introduced to fight cancer, but the number of T-cells able to invade tumor-bearing organs is insufficient
Solution Approach 1:
The patent applies parameter changes by using neurotransmitters and ion channel blockers to modulate T-cell surface properties and signaling pathways. Specifically, dopamine agonists and GnRH-II agonists bind to receptors on T-cells, triggering intracellular signaling that upregulates CD3 zeta expression and enhances T-cell invasion capabilities into tumor-bearing organs, thereby increasing both the quantity and effectiveness of invading T-cells
2Reliability
If T-cells are exposed to neurotransmitters and ion channel blockers to upregulate CD3 zeta expression, then T-cell invasion ability is enhanced, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent applies preliminary action by preparing a complete mixing device kit that contains all necessary components (neurotransmitters, ion channel blockers, mixing chambers, filtration systems) before the actual T-cell treatment. This pre-assembled kit simplifies the procedural complexity by providing turnkey functionality, allowing clinicians to simply connect the device to the patient's T-cell collection system without managing multiple separate reagents and equipment
3Reliability
If a mixing device is used to expose T-cells to boosting substances under sterile conditions, then T-cell boosting is effective, but the device complexity increases
Solution Approach 1:
The patent applies merging by integrating multiple critical functions into a single unified mixing device: the device combines sterile barrier functions (via filtration membranes and sealed chambers), mixing capabilities (via controlled fluid delivery and agitation mechanisms), and substance delivery (via syringe pumps and reservoirs) into one integrated system. This consolidation maintains sterility reliability while reducing operational complexity compared to using separate devices for each function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases CD3 zeta expression and TNF-alpha secretion in T-cells, enhancing their ability to invade and combat cancer and infectious organisms, improving treatment outcomes for cancer and immunodeficiency diseases.
Implementation Method 1
neurotransmitters like dopamine and GnRH-II, along with specific ion channel blockers, to upregulate CD3 zeta expression and enhance T-cell activity
Implementation Method 2
mixing device providing hermetically-sealed conditions effective to maintain sterility in both substances during the mixing/boosting
Data Source
AI summary
A method and device for augmenting the ability of T-cells, NK cells and other body cells, of a patient for fighting disease and invading diseased tissue, and for elevating the level of CD3 zeta expression in T cells for better functioning of these T-cells and their augmented capability to eliminate cancer and infectious organisms, by exposing, for a predetermined exposure period, the first substance of T-cell or other cells to a second substance having a T-cell-boosting capability, such as, but not limited to CD3 zeta elevating capability, increased CXCR4, CD147, 67-kDa laminin receptor and/or any other key receptor in T-cells capability, increased tissue invasion capability, TNFa elevating capability, to augment the ability of the separated cells to fight the disease; and following the predetermined exposure period, reintroducing the first substance of T-cells back into the blood of the subject. The first substance is exposed to the second substance by mixing the two substances in a mixing device providing hermetically-sealed conditions effective to maintain sterility in both substances during the mixing and to maintain tissue culture conditions required for the cells viability thereof and for the required exposure period.